Laila König1,2, Juliane Hörner-Rieber3,4, Denise Bernhardt3,4, Adriane Hommertgen3,4, Stefan Rieken3,4, Jürgen Debus3,4, Klaus Herfarth3,4. 1. Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. Laila.Koenig@med.uni-heidelberg.de. 2. National Center for Radiation Research in Oncology (NCRO), Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. Laila.Koenig@med.uni-heidelberg.de. 3. Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. 4. National Center for Radiation Research in Oncology (NCRO), Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Abstract
PURPOSE: Retrospective study of effectiveness, toxicity, and relapse patterns after low-dose radiotherapy (LDRT) in patients with low-grade lymphomas. METHODS: 47 patients (median age 64 years) with 50 lesions were treated with LDRT (2 × 2 Gy). In 60%, LDRT was the primary and curative treatment, in 40% offered as second-line therapy in recurrent disease. Histology included follicular (57%) and marginal zone lymphomas (43%). Patients were followed-up regularly clinically (skin) and with CT or MRI scans. RESULTS: Median follow-up was 21 months. 84% of the lesions were extranodal disease (32% orbit, 14% salivary glands, 30% skin, and 8% others). Most lesions were ≤5 cm (90%) with a singular affection (74%). 26% of the patients received rituximab simultaneously. Overall response rate (ORR) was 90% (all lesions), 93.3% (primary treatment), and 85% (recurrence treatment); p = 0.341. 2‑year Local progression-free survival (LPFS) for all, curative, and palliative patients was 91.1%, 96.7%, and 83.8%, respectively; p = 0.522. Five relapses were detected: three infield only, and were therefore treated with LDRT or subsequent local RT of 30 Gy. Two patients showed an in- and outfield progression and were consequently treated with chemotherapy. Predictive factors for higher LPFS were tumor size ≤5 cm (p = 0.003), ≤2 previous treatments (p = 0.027), no skin involvement (p = 0.05), singular affection (p = 0.075), and simultaneous rituximab application (p = 0.148). LDRT was tolerated well, without detectable acute or long-term side effects. CONCLUSION: Primary LDRT is an effective treatment with high ORR and long-lasting remissions in a subset of patients with low-grade lymphoma, and may therefore be a curative treatment option for patients with low tumor burden. LDRT with the CD20 antibody obinutuzumab will soon be tested in a prospective multicenter trial.
PURPOSE: Retrospective study of effectiveness, toxicity, and relapse patterns after low-dose radiotherapy (LDRT) in patients with low-grade lymphomas. METHODS: 47 patients (median age 64 years) with 50 lesions were treated with LDRT (2 × 2 Gy). In 60%, LDRT was the primary and curative treatment, in 40% offered as second-line therapy in recurrent disease. Histology included follicular (57%) and marginal zone lymphomas (43%). Patients were followed-up regularly clinically (skin) and with CT or MRI scans. RESULTS: Median follow-up was 21 months. 84% of the lesions were extranodal disease (32% orbit, 14% salivary glands, 30% skin, and 8% others). Most lesions were ≤5 cm (90%) with a singular affection (74%). 26% of the patients received rituximab simultaneously. Overall response rate (ORR) was 90% (all lesions), 93.3% (primary treatment), and 85% (recurrence treatment); p = 0.341. 2‑year Local progression-free survival (LPFS) for all, curative, and palliative patients was 91.1%, 96.7%, and 83.8%, respectively; p = 0.522. Five relapses were detected: three infield only, and were therefore treated with LDRT or subsequent local RT of 30 Gy. Two patients showed an in- and outfield progression and were consequently treated with chemotherapy. Predictive factors for higher LPFS were tumor size ≤5 cm (p = 0.003), ≤2 previous treatments (p = 0.027), no skin involvement (p = 0.05), singular affection (p = 0.075), and simultaneous rituximab application (p = 0.148). LDRT was tolerated well, without detectable acute or long-term side effects. CONCLUSION: Primary LDRT is an effective treatment with high ORR and long-lasting remissions in a subset of patients with low-grade lymphoma, and may therefore be a curative treatment option for patients with low tumor burden. LDRT with the CD20 antibody obinutuzumab will soon be tested in a prospective multicenter trial.
Authors: Ira Skvortsova; Sergej Skvortsov; Bela-Andre Popper; Alfred Haidenberger; Maria Saurer; Andreas R Gunkel; Heinz Zwierzina; Peter Lukas Journal: J Radiat Res Date: 2006-06 Impact factor: 2.724
Authors: Joachim Yahalom; Tim Illidge; Lena Specht; Richard T Hoppe; Ye-Xiong Li; Richard Tsang; Andrew Wirth Journal: Int J Radiat Oncol Biol Phys Date: 2015-05-01 Impact factor: 7.038
Authors: Tim Illidge; Lena Specht; Joachim Yahalom; Berthe Aleman; Anne Kiil Berthelsen; Louis Constine; Bouthaina Dabaja; Kavita Dharmarajan; Andrea Ng; Umberto Ricardi; Andrew Wirth Journal: Int J Radiat Oncol Biol Phys Date: 2014-05-01 Impact factor: 7.038
Authors: Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl Journal: J Clin Oncol Date: 2007-01-22 Impact factor: 44.544
Authors: Chelsea C Pinnix; Bouthaina S Dabaja; Sarah A Milgrom; Grace L Smith; Zeinab Abou; Loretta Nastoupil; Jorge Romaguera; Francesco Turturro; Nathan Fowler; Luis Fayad; Jason Westin; Sattva Neelapu; Michelle A Fanale; Maria A Rodriguez; Frederick Hagemeister; Hun Ju Lee; Yasuhiro Oki; Michael Wang; Felipe Samaniego; Linda Chi; Bita Esmaeli Journal: Head Neck Date: 2017-04-03 Impact factor: 3.147
Authors: R L M Haas; Ph Poortmans; D de Jong; M Verheij; M van der Hulst; J P de Boer; H Bartelink Journal: Eur J Cancer Date: 2005-08 Impact factor: 9.162
Authors: Carolina E Fasola; Jennifer C Jones; Derek D Huang; Quynh-Thu Le; Richard T Hoppe; Sarah S Donaldson Journal: Int J Radiat Oncol Biol Phys Date: 2013-05-29 Impact factor: 7.038
Authors: Khaled Elsayad; Gabriele Reinartz; Michael Oertel; Stephan Rehn; Jens Eismann; Sergiu Scobioala; Hendrik Berssenbrügge; Nicole Eter; Carsten Weishaupt; Hartmut H Schmidt; Birte Friedrichs; Inga Grünewald; Wolfgang Hartmann; Georg Lenz; Eva Wardelmann; Normann Willich; Hans Theodor Eich Journal: Strahlenther Onkol Date: 2019-11-15 Impact factor: 3.621
Authors: Gustavo R Sarria; Carla M Cabrera; Gustavo J Sarria; Mario Buitrago; Paola Fuentes; Solon Serpa; Frank A Giordano Journal: J Contemp Brachytherapy Date: 2020-06-30
Authors: Jeremy P M Flanagan; Michael Ng; Awet Z Kibrom; Robin J A Filshie; Richard J Stawell; Roderick F O'Day Journal: J Ophthalmic Inflamm Infect Date: 2022-03-05
Authors: M Oertel; K Elsayad; R Engenhart-Cabillic; G Reinartz; C Baues; H Schmidberger; D Vordermark; S Marnitz; P Lukas; C Ruebe; A Engert; G Lenz; H T Eich Journal: Strahlenther Onkol Date: 2020-10-30 Impact factor: 3.621
Authors: Brandon S Imber; Karen W Chau; Jasme Lee; Jisun Lee; Dana L Casey; Joanna C Yang; N Ari Wijentunga; Annemarie Shepherd; Carla Hajj; Shunan Qi; Monica R Chelius; Paul A Hamlin; M Lia Palomba; Erel Joffe; Zhigang Zhang; Andrew D Zelenetz; Gilles A Salles; Joachim Yahalom Journal: Blood Adv Date: 2021-10-26
Authors: Jong Yun Baek; Do Hoon Lim; Dongryul Oh; Heerim Nam; Jae J Kim; Jun Haeng Lee; Byung-Hoon Min; Hyuk Lee Journal: Cancer Res Treat Date: 2021-04-01 Impact factor: 4.679